Freeline Therapeutics Holdings Plc (FRLN)

NASDAQ
0.750
+0.014(+1.89%)
After Hours
0.750
0.000(0.00%)
- Real-time Data
  • Volume:
    16,025
  • Day's Range:
    0.726 - 0.780
  • 52 wk Range:
    0.650 - 15.400

FRLN Overview

Prev. Close
0.736
Day's Range
0.726-0.78
Revenue
-
Open
0.78
52 wk Range
0.65-15.4
EPS
-3.58
Volume
16,025
Market Cap
46.75M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
208,132
P/E Ratio
-
Beta
-
1-Year Change
-91.57%
Shares Outstanding
62,345,313
Next Earnings Date
Nov 03, 2022
What is your sentiment on Freeline?
or
Market is currently closed. Voting is open during market hours.

Freeline Therapeutics Holdings Plc Company Profile

Freeline Therapeutics Holdings Plc Company Profile

Employees
236

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company’s products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuySellSellStrong Sell
Technical IndicatorsSellNeutralNeutralStrong SellSell
SummaryNeutralNeutralNeutralStrong SellStrong Sell